Here, we report development of AAV-carried therapeutic gene construct consisting of cell-specific promoter driven Multi-Characteristic Opsin (MCO-II) to target inhibitory cells of ACC. MCO-II is highly sensitive to light and can be activated at low intensity, thus requiring a very low power budget. This along with red-light sensitiveness of MCO allows deep penetration with a minimally invasive implant. We developed a wireless Bluetooth Optogenetic Pain Modulator device for control of the dose of optogenetic stimulation. We demonstrated that red light stimulation of inhibitory neurons in ACC expressing MCO-II leads to significant reduction in pain response in fully awake animals.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.